Other Clinical Trial - A Phase 1, Single-arm, Open-label, Dose-escalation

See also
Status	Clinical Trial	Phase
Terminated	`NCT01020812` - Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma	Phase 1/Phase 2
Recruiting	`NCT04443322` - Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )	N/A
Completed	`NCT02305459` - CIRSE Registry for SIR-Spheres Therapy
Terminated	`NCT00791544` - Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma	Phase 1/Phase 2
Active, not recruiting	`NCT04682847` - Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
Completed	`NCT02424955` - Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation	N/A
Completed	`NCT03775863` - AFP Model and Liver Transplantation.
Not yet recruiting	`NCT04825470` - Liver Transplantation for Unresectable GIST Liver Metastases	N/A
Completed	`NCT01717729` - Hepatocellular Carcinoma Treated With Iodine-125 Implantation	Phase 3
Completed	`NCT03178409` - Combined HCC-MFCCC	N/A
Suspended	`NCT04955808` - Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
Recruiting	`NCT01380392` - The Illness of Uncertainty, Personality and Coping Strategies in Patients With Hepatocellular Carcinoma	N/A
Withdrawn	`NCT01744639` - Analysis of Body Composition in Patients With Hepatocellular Carcinoma in Radioablation	N/A
Completed	`NCT01482442` - SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma	Phase 3
Active, not recruiting	`NCT01272557` - Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial	Phase 2
Completed	`NCT00328770` - De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma	Phase 2/Phase 3
Completed	`NCT05681234` - Clinical Application of 18F-labeled RD2 PET/CT Imaging in the Diagnosis and Treatment of Small Liver Carcinoma	N/A
Terminated	`NCT00767234` - Permission to Collect Blood Over Time for Research	N/A
Active, not recruiting	`NCT02465060` - Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	Phase 2
Recruiting	`NCT04288323` - Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis	Phase 4

NCT number	NCT06144385
Study type	Interventional
Source	Shanghai Ming Ju Biotechnology Co., Ltd.
Contact	Tao Zhang, MD, PhD
Phone	+86 027-85726375
Email	1277577866@qq.com
Status	Recruiting
Phase	Phase 1
Start date	March 24, 2022
Completion date	December 2024

A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms